The new finding comes from an analysis of pesticide use and prostate cancer incidence in over 3,100 U.S. counties.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A groundbreaking approach slows tumor growth while boosting the immune system’s defense against cancer cells. Prostate cancer ranks as the second most common cancer among men globally. Despite recent ...

“We remain on track for phase 2b and phase 3 topline data in non-metastatic, localized prostate cancer for CAN-2409 in the fourth quarter of 2024, and hope we will deliver the data and regulatory ...

Investigators conducted a trial of MRI as a screening tool to reduce overdetection of insignificant prostate cancer.

She gets me through the day," says Hartter. So the reason a 73-year-old man with stage 4 cancer gets up and rides most days ...

Overtreatment of prostate cancer is increasing in the United States among men with limited life expectancy, a new s ...

Researchers at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2024 and provided an update on the company’s recent developments.

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...